Neoadjuvant pertuzumab a costly addition for treating HER2+ breast cancer in Portugal
Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Neoadjuvant Therapy | Portugal Health